Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 202-CoV in Healthy Adults
NCT04982068Phase 1Unknown
- Sponsor
- Shanghai Zerun Biotechnology Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZR202-CoV in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Shanghai Zerun Biotechnology Co., Ltd. Primary endpoints: Incidence of solicited adverse events and Incidence of unsolicited adverse events. Status: unknown.
02
Drugs
ZR202-CoV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04982068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982068.